Inhibitor Therapeutics OTC Stock Top Insiders

INTI Stock  USD 0.04  0.00  0.00%   
Inhibitor Therapeutics employs about 1 people. The company is managed by 2 executives with a total tenure of roughly 3 years, averaging almost 1.0 years of service per executive, having 0.5 employees per reported executive. Assessment of Inhibitor Therapeutics' management performance can provide insight into the firm performance.
CPA CPA  Insider
Treasurer, CFO
Nicholas Virca  Insider
Pres CEO
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inhibitor Therapeutics. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in persons.

Inhibitor Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (2.1127) % which means that it has lost $2.1127 on every $100 spent on assets. This is way below average. Inhibitor Therapeutics' management efficiency ratios could be used to measure how well Inhibitor Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Inhibitor Therapeutics Workforce Comparison

Inhibitor Therapeutics is rated below average in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 40.0. Inhibitor Therapeutics holds roughly 1.0 in number of employees claiming about 2.5% of stocks in Biotechnology industry.

Inhibitor Therapeutics Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Inhibitor Therapeutics Price Series Summation is a cross summation of Inhibitor Therapeutics price series and its benchmark/peer.

Inhibitor Therapeutics Notable Stakeholders

An Inhibitor Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Inhibitor Therapeutics often face trade-offs trying to please all of them. Inhibitor Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Inhibitor Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.

About Inhibitor Therapeutics Management Performance

The success or failure of an entity such as Inhibitor Therapeutics often depends on how effective the management is. Inhibitor Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Inhibitor management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Inhibitor management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people.
The data published in Inhibitor Therapeutics' official financial statements typically reflect Inhibitor Therapeutics' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Inhibitor Therapeutics' quantitative information. For example, before you start analyzing numbers published by Inhibitor accountants, it's essential to understand Inhibitor Therapeutics' liquidity, profitability, and earnings quality within the context of the Healthcare space in which it operates.

Inhibitor Therapeutics Workforce Analysis

Traditionally, organizations such as Inhibitor Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Inhibitor Therapeutics within its industry.

Inhibitor Therapeutics Manpower Efficiency

Return on Inhibitor Therapeutics Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee298.6K
Net Loss Per Executive149.3K
Working Capital Per Employee1.7M
Working Capital Per Executive826.4K

Complementary Tools for Inhibitor OTC Stock analysis

When running Inhibitor Therapeutics' price analysis, check to measure Inhibitor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibitor Therapeutics is operating at the current time. Most of Inhibitor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibitor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibitor Therapeutics' price. Additionally, you may evaluate how the addition of Inhibitor Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
CEOs Directory
Screen CEOs from public companies around the world
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Insider Screener
Find insiders across different sectors to evaluate their impact on performance